News

April 24, 2017

Biogen Releases New Data from Cherish and Nurture Trials

Biogen Releases New Data from Cherish and Nurture Trials

Biogen will present Phase 3 end of study SPINRAZA® (nusinersen) data from CHERISH, which demonstrated a highly statistically significant and clinically meaningful improvement in motor function in children with later-onset (most likely to develop Type 2 or Type 3) spinal muscular atrophy...

READ MORE   |  

Topics: Clinical Trials, Front Page News

March 29, 2017

Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients with SMA

Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients with SMA

Cytokinetics, Inc. today announced that the second cohort of the Phase 2 clinical trial of CK-2127107 in patients with spinal muscular atrophy (SMA), is open to...

READ MORE   |  

Topics: Clinical Trials, Front Page News

March 21, 2017

Genentech Roche Releases Community Letter with Clinical Trial Updates

Genentech Roche Releases Community Letter with Clinical Trial Updates

Genentech Roche provided the following community statement with clinical trial updates for SUNFISH (Type 2/3), FIREFISH (Type 1) and JEWELFISH. 

Dear SMA community,

At Genentech (A Member of the Roche Group) we are committed to addressing the urgent needs of...

READ MORE   |  

Topics: Clinical Trials, Front Page News

Items 1 - 3 of 91  12345678910Next

© 2014 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software